| Income statement (USD) | Q2 2026 ended Jun 28, 2026 | Q1 2026 ended Mar 29, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 28, 2025 | Q2 2025 ended Jun 29, 2025 | Q1 2025 ended Mar 30, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 29, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.03B | 14.45B | 17.56B | 16.65B | 14.65B | 13.71B | 17.76B | 17.70B |
| Cost of revenue | 4.09B | 3.55B | 5.27B | 4.17B | 3.78B | 2.85B | 5.91B | 5.26B |
| Gross profit | 10.94B | 10.90B | 12.29B | 12.48B | 10.88B | 10.87B | 11.85B | 12.44B |
| Research and development | 2.81B | 2.49B | 3.21B | 2.55B | 2.48B | 2.20B | 3.04B | 2.60B |
| Selling, general and admin | 3.41B | 2.96B | 4.16B | 3.19B | 3.42B | 3.03B | 4.27B | 3.24B |
| Interest expense | 667.00M | 668.00M | 711.00M | 652.00M | 654.00M | 654.00M | 739.00M | 783.00M |
| Income before tax | -653.00M | 3.17B | -1.64B | 3.33B | 3.04B | 2.79B | -10.00M | 4.71B |
| Income tax | -407.00M | 461.00M | -2.00M | -216.00M | 141.00M | -189.00M | -421.00M | 234.00M |
| Net income | -248.00M | 2.69B | -1.65B | 3.54B | 2.91B | 2.97B | 410.00M | 4.46B |
| EPS | -0.04 | 0.47 | -0.29 | 0.62 | 0.51 | 0.52 | 0.07 | 0.79 |
| EPS (diluted) | -0.04 | 0.47 | -0.29 | 0.62 | 0.51 | 0.52 | 0.07 | 0.78 |
| Diluted shares | 5.70B | 5.73B | 3.00M | 5.71B | 5.71B | 5.71B | 1.00M | 5.71B |
| Dividends per share | 0.86 | 0.00 | 0.86 | 0.00 | 0.86 | 0.00 | 0.85 | 0.00 |
From Pfizer's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.